The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review
- 123 Downloads
Currently, trastuzumab is one of the key drugs in the treatment strategy for HER2-positive breast cancer. Although metastatic breast cancer is unlikely to be cured, some HER2-positive patients have survived for a long time with complete response to trastuzumab therapy. In HER2-positive metastatic breast cancer, single agent trastuzumab is effective and less toxic. Combination of trastuzumab with cytotoxic drugs is also effective. Therefore, major guidelines recommend using trastuzumab as a key drug in the management of HER2-positive metastatic breast cancer. However, many clinical questions still need to be solved. In this article, recent evidence was reviewed to find some answers about these issues.
KeywordsMetastatic breast cancer HER2-positive Trastuzumab
- 2.National Comprehensive Cancer Network (NCCN). http://www.nccn.org/professionals/physician_gls/default.asp.
- 5.Mackey JR, Kaufman B, Clemens M, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Jones A. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2006; abstract 3.Google Scholar
- 6.Nakagami K, Inoue K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Ohashi Y, Sano M, Noguchi S. Randomized Phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2008; abstract 3132.Google Scholar
- 9.Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–85.PubMedCrossRefGoogle Scholar
- 11.Theodoulou M, Campos SM, Batist G, Winer E, Norton L, Hudis C, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol. 2002;21:55a. abstract.Google Scholar
- 14.Tokuda Y, Umemura S, Saito Y, Suzuki Y. Enhanced anti-tumor effect of trastuzumab combined with less cardiotoxic anthracycline, amrubicin, in HER2 positive human cancer xenografts in athymic mice. J Clin Oncol. 2008;26:abstract 14641.Google Scholar
- 15.Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.PubMedCrossRefGoogle Scholar
- 16.Bontenbal M, Seynaeve C, Stouthard J, Bos M, Braun H, Erdkamp FL, et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in Her2-neu positive, metastatic breast cancer (HERTAX study). J Clin Oncol. 2008;26:44s. abstract 1014.CrossRefGoogle Scholar
- 17.Hayes D. Systemic therapy for HER2-positive metastatic breast cancer. UpToDate version 16.3.Google Scholar
- 19.Fujimoto-Ouchi K, Sekiguchi F, Mori K. Preclinical study of continuous administration of trastuzumab as combination therapy after disease progression with trastuzumab monotherapy. Proc Amer Assoc Cancer Res. 2005;46:abstract 5062.Google Scholar
- 20.Von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al. Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol. 2008;26:47s. abstract 1025.Google Scholar
- 21.O’Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2 + metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26:44s. abstract 1015.CrossRefGoogle Scholar